WO2015108372A1 - Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci - Google Patents

Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci Download PDF

Info

Publication number
WO2015108372A1
WO2015108372A1 PCT/KR2015/000493 KR2015000493W WO2015108372A1 WO 2015108372 A1 WO2015108372 A1 WO 2015108372A1 KR 2015000493 W KR2015000493 W KR 2015000493W WO 2015108372 A1 WO2015108372 A1 WO 2015108372A1
Authority
WO
WIPO (PCT)
Prior art keywords
osmotin
glutamate
expression
treatment
present
Prior art date
Application number
PCT/KR2015/000493
Other languages
English (en)
Korean (ko)
Inventor
김명옥
박현영
Original Assignee
경상대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경상대학교산학협력단 filed Critical 경상대학교산학협력단
Publication of WO2015108372A1 publication Critical patent/WO2015108372A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a composition for preventing, ameliorating or treating neurological diseases caused by excitatory toxicity or synaptic dysfunction, and a method for preventing or treating neurological diseases using the same.
  • the present invention relates to a pharmaceutical composition or a food composition for preventing, ameliorating or treating a neurological disease caused by excitatory toxicity or synaptic dysfunction, including osmotin as an active ingredient, and using the composition, excitatory toxicity or synapse A method for preventing or treating a neurological disorder caused by a dysfunction.
  • Excitotoxicity refers to a pathological process in which nerve cells are damaged or killed by nerve cells being overstimulated by neurotransmitters such as glutamate or the like. Excitatory toxicity-mediated damage or death of nerve cells has been reported in various central nervous system diseases including ischemia and neurodegenerative diseases.
  • Osmotin is a multifunctional plant protein derived from Nicotiana tabacum and the like and has a molecular weight of about 24 kDa.
  • Osmotin is a protein belonging to the family of pathogenesis related-5 (PR-5) that provides plants with osmotolerance and exhibits antimicrobial activity.
  • PR-5 pathogenesis related-5
  • Osmotin is believed to be a structural and functional homologue with the mammalian hormone adiponectin and can act biologically as an adiponectin counterpart.
  • Korean Patent No. 10-1308232 discloses a composition for treating neurodegenerative diseases by alcohol containing osmotin, but the registered patent discloses an alcohol of osmotin. Efficacy of the neurodegenerative diseases induced by the present invention was only identified, and no effect was suggested for the neurological diseases caused by excitatory toxicity or synaptic dysfunction.
  • the present inventors have diligently tried to determine the effect of osmotin in neurological diseases caused by excitatory toxicity or synaptic dysfunction.
  • the osmotin is an AMPA ( ⁇ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor.
  • AMPA ⁇ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
  • An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of neurological diseases caused by excitatory toxicity or synaptic dysfunction comprising osmotin as an active ingredient.
  • Another object of the present invention to provide a food composition for the prevention or improvement of neurological diseases caused by excitatory toxicity or synaptic dysfunction comprising osmotin as an active ingredient.
  • Still another object of the present invention is to provide a method for preventing or treating neurological diseases caused by excitatory toxicity or synaptic dysfunction using the composition.
  • composition containing the osmotin of the present invention as an active ingredient may be usefully used as a substance for preventing or treating excitatory toxicity or synaptic dysfunction induced by excessive stimulation of a neurotransmitter, and the neurological diseases caused thereby.
  • the effect of inhibiting the expression of the AMPA glutamate receptor is excellent, particularly the effect of preventing or treating excitatory or synaptic dysfunction induced by glutamate, and the neurological diseases caused thereby.
  • FIG. 1A and 1B show changes in expression of AMPA glutamine receptor (AMPAR), p-AMPAR and CaMKII in the cortex and hippocampus of osmotin treatment.
  • AMPAR AMPA glutamine receptor
  • p-AMPAR p-AMPAR
  • CaMKII CaMKII
  • 1C and 1D show changes in expression of p-CREB and synaptopycin in the cortex and hippocampus of the brain following osmotin treatment.
  • 2A and 2B show changes in expression of p53, Bax and Bcl-2 in the cortex and hippocampus of the brain following osmotin treatment.
  • 2C and 2D show changes in the expression of cytochrome-C, caspase-3 and PARP-1 in the cortex and hippocampus of the brain following osmotin treatment.
  • 3A and 3B show changes in the degree of DNA fragmentation in three regions of the hippocampus (CA1, CA3 and DG) following osmotin treatment.
  • 4A and 4B show changes in the expression of p-JNK, p-PI3K and p-Akt in cortex and hippocampus following osmotin treatment.
  • 4C and 4C show changes in expression of p-JNK and p-PI3K in CA1 region of hippocampus following osmotin treatment.
  • 5A and 5B show changes in distribution and colocation of p53 and p-Akt in CA1 region of hippocampus following osmotin treatment.
  • 5C and 5D show changes in the distribution and colocation of p53 and caspase-3 in the CA1 region of the hippocampus following osmotin treatment.
  • FIG. 6 is a simplified schematic of the mechanism of action of osmotin on biomechanisms induced by glutamate.
  • C is a control group
  • Glu is a glutamate treatment group
  • Os is an osmotin treatment group
  • Glu + Os means a glutamate and osmotin treatment group
  • the present invention provides a pharmaceutical composition for the prevention or treatment of neurological diseases caused by excitatory toxicity or synaptic dysfunction comprising osmotin as an active ingredient as one embodiment.
  • osmotin is a multifunctional plant protein derived from Nicotiana tabacum and the like, and is composed of about 150 to 250 amino acids depending on the individual, and has a molecular weight of about 24 kDa. It is known. Osmotin is a member of the PR-5 (Pathogenesis related-5) family that provides plants with osmotolerance and exhibits antimicrobial activity. It is believed that it can act as an adiponectin counterpart.
  • Korean Patent No. 10-1308232 discloses that osmotin exhibits an effect of inhibiting the death of alcohol-induced nerve cells, and by using the neurodegenerative disease caused by alcohol A therapeutic composition is provided.
  • the registered patent is limited to alcohol-induced neurodegenerative diseases, and there is no disclosure about neurological diseases induced by excitatory toxicity or synaptic dysfunction among neurological diseases, and the efficacy of osmotin on such neurological diseases. There was no suggestion about.
  • osmotin has an effect of treating neurological diseases caused by excitatory toxicity or synaptic dysfunction, and particularly, has a turbulent effect in the treatment of excitatory toxicity or synaptic dysfunction caused by glutamate overstimulation. It was confirmed.
  • Neurodegenerative diseases caused by alcohol are neurological diseases in which neuronal cell death is induced by alcohol.
  • the osmotin inhibits neuronal cell death, but the excitatory toxicity or synaptic function of the present invention.
  • Neurological diseases induced by the disorder are induced by excessive stimulation by neurotransmitters (particularly, glutamate).
  • the first clarification of glutathione receptor expression inhibition of osmotin and the like is performed. There is a difference in that it was first disclosed the therapeutic use of neurological diseases caused by excessive stimulation.
  • the osmotin can be used without limitation in its origin or type.
  • the osmotin may be separated from various plants or artificially synthesized according to genetic engineering methods, or may be purchased from domestic and foreign companies.
  • the neurological disease caused by the excitatory toxicity or synaptic dysfunction may be included without limitation to the type or condition of the disease, as long as it is induced by the excitatory toxicity or synaptic dysfunction.
  • the neurological disorder may be a mental neurological disorder, and examples of the mental neurological disorder include, but are not limited to, depression, schizophrenia, OCD, anxiety neurosis, and the like.
  • the neurological diseases include neurological diseases induced by nerve damage caused by excitotoxicity or synaptic dysfunction.
  • prevention means any action that inhibits or delays neurological symptoms caused by excitatory or synaptic dysfunction by administering the pharmaceutical composition of the present invention to a subject.
  • treatment refers to any action by which the pharmaceutical composition of the present invention is administered to a subject to improve or benefit neurological symptoms caused by excitatory toxicity or synaptic dysfunction.
  • the prevention or treatment of neurological diseases caused by the excitatory toxicity or synaptic dysfunction using the pharmaceutical composition comprising the osmotin of the present invention as an active ingredient may be performed by reducing expression of AMPA glutamate receptor or decreasing phosphorylation of AMPA glutamate receptor. Can be.
  • the term “decreased expression” or “increased expression” means that the expression of the protein is reduced or increased at the level of transcription or the activity of the protein as compared to the condition prior to treatment of the composition comprising the osmotin of the invention. It means all cases that are reduced or increased.
  • Said “reduced expression” or “increased expression” is for the purpose of the present invention, more preferably the expression of the protein of interest increased or decreased compared to the normal state induces excitatory or synaptic dysfunction, administration of the composition of the present invention It means all cases where the expression of the protein is reduced or increased than the condition before the administration of the composition of the present invention.
  • AMPA ⁇ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor
  • Prevention or treatment of neurological diseases caused by the excitatory toxicity or synaptic dysfunction using the pharmaceutical composition comprising the osmotin of the present invention as an active ingredient, may be performed by increasing the expression of synaptopycin.
  • synaptophysin is a glycoprotein of about 30 kDa present in the synaptic vesicle of nerve cells or secretory cells in the nerve, also known as synaptic vesicle protein p38. Mean protein.
  • the expression of synaptopycin was significantly reduced when glutamate was treated in the rat at 7 days of age, but the osmotin treatment of the present invention after the glutamate treatment resulted in the reduction of synaptopycin. It was confirmed that the expression level is increased (Experimental Example 2).
  • the prevention or treatment of neurological diseases caused by the excitatory toxicity or synaptic dysfunction using the pharmaceutical composition comprising the osmotin of the present invention as an active ingredient may be performed by reducing the expression of CaMKII.
  • CaMKII (Ca 2+ / calmodulin-depandent protein kinase II) is a kind of serine / threonine-specific protein kinase, and means a kinase regulated by a Ca 2+ / calmodulin complex.
  • the expression of CaMKII was significantly increased when glutamate was treated in the rat at 7 days of age, but as a result of treating the osmotin of the present invention after the glutamate treatment, the expression level of CaMKII was increased. It was confirmed that the decrease by (experimental example 1).
  • JNK / PI3K / Akt pathway is a kind of intracellular signal transduction pathway, and a factor involved in the pathway "JNK” means "c-Jun N-terminal kinase” and " PI3K “means” Phosphoinositide 3-kinase "and” Akt “means” Protein kinase B (PKB) ".
  • p-JNK expression was increased and p-PI3K and p-Akt expression was reduced when glutamate was treated in rats of 7 days of age, but the osmotin of the present invention after the glutamate treatment As a result, it was confirmed that the increased expression level of p-JNK was significantly decreased, and the expression levels of p-PI3K and p-Akt were decreased significantly (Experimental Example 4).
  • the pharmaceutical composition comprising the osmotin of the present invention as an active ingredient also exhibits the effect of inhibiting apoptosis of nerve cells.
  • apoptosis is a form of a cell controlled by genes and kills itself, and is a concept distinguished from necrosis, which is necrosis or pathological death of cells. Also called.
  • the expression changes of p53, Bcl-2, Bax, which are known to be involved in apoptosis, the delivery of mitochondrial cytochromes to the cell substrate and the activation of caspase-3 and PARP-1 were observed. It was.
  • p53 used in the present invention is one of tumor suppressor factors, and is known to play a role in inhibiting abnormal proliferation of cells and inducing cancer cells to die.
  • Bcl-2 is a type of Bcl-2 family protein having a molecular weight of about 26 kDa and is known as an apoptosis inhibitor. Bcl-2 blocks apoptosis mediated by Fas antigen and TNF receptors, and overexpression of Bcl-2 inhibits apoptosis and is known to prolong cell life. Bcl-2 is also known to play a role in inhibiting the action of Bax and inhibiting the release of cytochrome C.
  • Bax is known as an apoptosis inducing factor and belongs to the Bcl-2 family because Bcl-2 and its gene sequence are similar.
  • Bax is activated, apoptosis is promoted and cell death is increased.
  • Bcl-2 is activated, apoptosis is suppressed and cell death is reduced.
  • treatment of glutamate in rats at 7 days of age increased the expression level of p53 protein and the Bax / Bcl-2 ratio, the delivery of mitochondrial cytochrome C and the caspase-3 and PARP-1.
  • Activation was promoted, but as a result of treating the osmotin of the present invention after the glutamate treatment, all of the above aspects were found to be reversed, and it was confirmed that the apoptosis of nerve cells was suppressed (Experimental Example 3).
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, in addition to including osmotin as an active ingredient.
  • the "pharmaceutically acceptable” means that it is commonly used in the pharmaceutical field that does not impede the biological activity and properties of the compound to be administered without stimulating the organism upon administration thereof.
  • the type of the carrier is not particularly limited and any carrier can be used as long as it is commonly used in the art.
  • Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, and the like. Can be. These may be used alone or in combination of two or more thereof.
  • composition of the present invention may be used by adding other pharmaceutically acceptable additives, such as excipients, diluents, antioxidants, buffers or bacteriostatic agents, if necessary, fillers, extenders, wetting agents, disintegrants, dispersants, surfactants , Binders or lubricants may be additionally added and used.
  • additives such as excipients, diluents, antioxidants, buffers or bacteriostatic agents, if necessary, fillers, extenders, wetting agents, disintegrants, dispersants, surfactants , Binders or lubricants may be additionally added and used.
  • osmotin may be included in 0.00001% to 99.99% by weight based on the total weight of the pharmaceutical composition, preferably 1% to 99.99% by weight, more preferably 10 It may be included in the weight% to 99.99% by weight, more preferably 50% to 99.99% by weight, and may also be included in the total content of the pharmaceutical composition.
  • compositions of the present invention can be formulated and used in a variety of formulations suitable for oral or parenteral administration.
  • Non-limiting examples of the formulation for oral administration include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs, and the like. Can be mentioned.
  • a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin and the like; Excipients such as dicalcium phosphate and the like; Disintegrants such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax and the like can be used, and sweeteners, fragrances, syrups and the like can also be used.
  • a liquid carrier such as fatty oil may be additionally used in addition to the above-mentioned materials.
  • Non-limiting examples of the parenteral preparations include injection liquids, suppositories, respiratory inhalation powders, spray aerosols, ointments, application powders, oils, creams, and the like.
  • a sterile aqueous solution In order to formulate the pharmaceutical composition for parenteral administration, a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, an external preparation, and the like may be used.
  • a non-aqueous solvent and the suspension propylene glycol, polyethylene Glycols, vegetable oils such as olive oil, injectable esters such as ethyloleate and the like can be used.
  • the pharmaceutical composition of the present invention when the pharmaceutical composition of the present invention is formulated as an injection solution, the composition of the present invention is mixed with water with a stabilizer or buffer to prepare a solution or suspension, which may be used as an ampoule or vial. It may be formulated for unit administration.
  • a propellant or the like when the pharmaceutical composition of the present invention is formulated with an aerosol, a propellant or the like may be combined with the additive to disperse the dispersed concentrate or the wet powder.
  • composition of the present invention when formulated into an ointment, a cream, or the like, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide It may be formulated using such as carrier.
  • a pharmaceutically effective amount, effective dosage of the pharmaceutical composition of the present invention may vary depending on the method of formulating the pharmaceutical composition, the mode of administration, the time of administration and / or the route of administration, and the likeness of the reaction to be achieved by the administration of the pharmaceutical composition.
  • the type and extent of the subject, the type, age, weight, general state of health, condition or extent of the disease, sex, diet, excretion, components of the drug or other composition used concurrently or simultaneously with the subject Various factors and similar factors well known in the medical arts can be varied, and one of ordinary skill in the art can easily determine and prescribe a dosage effective for the desired treatment.
  • Administration of the pharmaceutical composition of the present invention may be administered once a day, may be divided into several times.
  • the pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
  • the pharmaceutical composition of the present invention for a more preferable effect, it may be administered in an amount of 0.01 mg / kg / day to 100 mg / kg / day, more preferably from 0.1 mg / kg / day to It may be administered in an amount of 70 mg / kg / day, more preferably 1 mg / kg / day to 50 mg / kg / day.
  • the administration may be administered one time, divided into several times, and the administration cycle may be appropriately selected.
  • the route of administration and mode of administration of the pharmaceutical composition of the present invention may be independent of each other, and are not particularly limited in the way, and may be any route of administration and mode of administration as long as the pharmaceutical composition can reach the desired site. Can follow.
  • the pharmaceutical composition may be administered by oral or parenteral administration.
  • parenteral administration method for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration or subcutaneous administration may be used, and the method of applying, spraying or inhaling the composition to a diseased site may also be used. May be, but is not limited to these.
  • a food composition for the prevention or improvement of neurological diseases caused by excitatory toxicity or synaptic dysfunction comprising osmotin as an active ingredient.
  • improvement means any action that at least reduces the parameters associated with alleviation or treatment of a condition, such as the degree of symptoms.
  • the food composition of the present invention is not particularly limited and includes a health functional food composition.
  • the health functional food composition of the present invention When used as a food additive, the composition may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the kind of the food is not particularly limited, and includes all foods in a general sense.
  • foods that can be added to the material include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, dairy products, including other noodles, gums, ice cream, various soups, drinks, tea , A drink, an alcoholic beverage, and a vitamin complex.
  • the health functional food composition of the present invention is a beverage composition
  • it may contain various flavors or natural carbohydrates and the like as additional ingredients, as in the usual beverage.
  • natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweeteners such as dextrin, cyclodextrin; Synthetic sweeteners such as saccharin and aspartame; and the like.
  • the proportion of the additional components added above may be appropriately determined by the choice of those skilled in the art.
  • the health functional food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin , Alcohols, carbonation agents used in carbonated beverages, and the like.
  • the health functional food composition of the present invention may contain a flesh for preparing natural fruit juice, fruit drink or vegetable drink. These components can be used independently or can be used in combination of 2 or more. The proportion of such additives may also be appropriately selected by those skilled in the art.
  • a method for preventing or treating neurological diseases caused by excitotoxicity or synaptic dysfunction comprising administering to a subject the pharmaceutical composition comprising osmotin as an active ingredient.
  • a method for preventing or ameliorating neurological diseases caused by excitatory toxicity or synaptic dysfunction comprising administering to a subject the food composition comprising osmotin as an active ingredient.
  • mammals means all animals, including mammals, including rats, domestic animals, humans, and the like.
  • osmotin was purified from salt-adapted cultured Nicotiana tabacum cells.
  • the endotoxin content of osmotin was ⁇ 0.03 EU / mg protein.
  • Brain sections of pups treated with saline, glutamate or glutamate + osmotin in Example 1 were analyzed 12 hours after drug treatment.
  • Transcardial perfusion was performed by treatment with 1 ⁇ phosphate buffered saline (PBS) and 4% ice-cold treated paraformaldehyde.
  • the brain tissue was then post-fixed in 4% paraformaldehyde and transferred to 20% Sukurose until the brain tissue sank to the bottom of the tube.
  • the brain was frozen in OCT (AO, USA) and then the brain was cut into 14 ⁇ m sections in the coronal plane using a CM 3050S cryostat (Leica, Germany). The brain sections were thawed-fixed to probes on positively charged slides (Fisher, USA).
  • a pre-stained protein ladder (GangNam-STAIN TM , iNtRon Biotechnology, Inc. Republic of Korea) containing a wide range of molecular weights from 10 kDa to 245 kDa was operated in parallel. was used. In order to minimize membrane blocking and non-specificity, blocking was performed using 5% (w / v) skim milk.
  • Antibodies used in immunoblotting to detect proteins include rabbit-derived anti-actin, anti-Bcl-2, anti-Bax and anti-caspase-3; Chlorine-derived anti-cytochrome c and anti-p53; And mouse-derived polyclonal antibodies anti-PARP-1 and anti-JNK (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
  • rabbit-derived anti-p-CREB (Ser133), anti-CaMKII, anti-p-Akt (Ser473), anti-p-PI3K (Y458 / Y199), anti-p-JNK (Thr183 / Tyr185), anti -AMPA, anti-p-AMPA (Ser845) and anti-synaptopycin (Cell Signaling Technology, Inc) were used.
  • Membrane-bound secondary antibodies were visualized using ECL detection reagents according to the manufacturer's instructions (Amersham Pharmacia Biotech, Uppsala, Sweden). The optical density of the band was then analyzed by densitometry using a computer-based Sigma Gel program version 1.0 (SPSS, Chicago, IL, USA).
  • the tissue-containing slides according to Example 2 were washed twice for 15 minutes in 0.01 M PBS and proteolytic enzyme K solution was added to the tissues and incubated at 37 ° C. for 5 minutes. The tissues were then incubated for 90 minutes in blocking solution containing 0.3% Triton X-100 and normal pig serum in PBS.
  • the primary antibodies (rabbit polyclonal p-Akt, p-PI3K and caspase-3 (Cell Signaling Technology, Inc), and goat polyclonal IgG p53 and p-JNK (Santa cruz); All present at 1: 100 in PBS) overnight at 4 ° C.
  • TUNEL staining was performed according to the recommendations of In Situ Cell Death Detection Kit Fluorescein (GenScript, NJ, USA). Glass cover slides were encapsulated on glass slides with an encapsulant and FITC filters were used for TUNEL staining (green color) detection. TUNEL-positive (green) staining patterns were obtained with a confocal laser scanning microscope (FluoView FV 1000, Olympus, Japan), and TUNEL-positive cells in different regions of each section were counted with a computer based program.
  • the band of Western blot was scanned and the optical density of the band was analyzed by densitometer using Sigma Gel System (SPSS Inc., Chicago, IL). Density values are expressed as mean ⁇ SEM. One-way analysis (ANOVA) of variables was performed to identify significant differences, followed by Student's t-test to identify the significance of differences among the treatment groups. P values less than 0.05 were considered significant (p ⁇ 0.05).
  • AMPA glutamate receptors are ligand-gated ion channels consisting of a combination of four different subunits, GluR1-4, wherein overexpression of glutamate receptors causes excitatory toxicity and may result in neuronal damage.
  • the rat cortex and hippocampus were observed 4 hours after the first subcutaneous injection of glutamate in rats after 7 days of birth, whereas the AMPA glutamate receptor protein (Glu2 / 3/4) was overexpressed, whereas the glutamate treatment was performed. Later, it was observed that protein expression levels of AMPA receptors were significantly reduced in the animal group treated with osmotin (FIGS. 1A and 1B).
  • Calmodulin-dependent kinase-II (CaMKII) is an important regulatory factor in the biochemical mechanism leading to neuronal cell death due to acute excitatory toxicity and excitatory toxicity when antagonists inhibit the action of CaMKII. By the death of nerve cells is reduced.
  • osmotin is effective in protecting the nerve against acute excitatory toxicity induced by glutamate (FIGS. 1A and 1B).
  • synaptophysin In order to analyze the inhibitory effect of glutamate and the beneficial effect of osmotin on synaptic plasticity, the expression level of synaptophysin was measured using Western blot. Specifically, 4 hours after the first subcutaneous injection of glutamate in rats after 7 days of birth, the brain cortex and hippocampus of the rats were observed, whereas synaptopycin was significantly reduced, but after the glutamate treatment. Osmotin-treated animals were found to have increased expression levels of synaptophycins (FIGS. 1C and 1D). This means that osmotin is effective in repairing synaptic dysfunction induced by glutamate in the cortex and hippocampus of the brain.
  • Excitotoxic damage induced by glutamate can lead to a wide range of p53-mediated neuronal damage. Therefore, the levels of different cellular apoptosis markers were measured to determine whether neuronal damage was induced 4 hours after glutamate (10 mg / kg) in rats 7 days after birth.
  • glutamate is expressed in the level of proapoptotic p53, the ratio of proapoptotic Bax and antiapoptotic Bcl-2, the delivery of mitochondrial cytochrome to cell substrate and caspa in both cortex and hippocampus of brain. Toxicity was observed to be induced by increasing the activation of aze-3 and PARP-1.
  • DNA damage is one of the typical features of cellular apoptosis.
  • TUNEL staining DNA cleavage analysis based on enzyme labeling at the free 3 'DNA end was performed to visualize damaged DNA.
  • P-JNK (c-Jun N-) in the cerebral cortex and hippocampus of animals treated with glutamate alone and rats treated with osmotin after glutamate treatment in rats after 7 days of birth using Western blot Terminal kinase) expression levels were measured.
  • Phosphoinositide 3-kinase PI3-K / Akt pathway is one of the important pro-survival pathways in neurons. Therefore, it was examined whether the pathway was relevant when glutamate was treated in the cortex and hippocampus of the brain.
  • p-Akt was found to co-locate with p53 mostly.
  • the treatment of glutamate alone inhibited the distribution of p-Akt (red) and increased the distribution of p53 (green) in the CA1 region of the hippocampus of the brain, whereas osmotin after glutamate treatment
  • the distribution of p-Akt and p53 induced by glutamate in the CA1 region of the hippocampus was reversed (Figs. 5A and 5B).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne : une composition destinée à prévenir, atténuer ou traiter des troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique; et une méthode destinée à prévenir ou traiter des troubles neurologiques en faisant appel à celle-ci. Plus particulièrement, la présente invention concerne : une composition pharmaceutique ou une composition alimentaire destinée à prévenir, atténuer ou traiter des troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine utilisée comme principe actif; et une méthode destinée à prévenir ou traiter des troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, en faisant appel à la composition.
PCT/KR2015/000493 2014-01-17 2015-01-16 Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci WO2015108372A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140006347A KR20150086429A (ko) 2014-01-17 2014-01-17 오스모틴을 포함하는 흥분독성 또는 시냅스 기능 장애에 의한 신경 질환의 예방 또는 치료용 조성물, 및 이를 이용한 신경 질환의 예방 또는 치료 방법
KR10-2014-0006347 2014-01-17

Publications (1)

Publication Number Publication Date
WO2015108372A1 true WO2015108372A1 (fr) 2015-07-23

Family

ID=53543192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/000493 WO2015108372A1 (fr) 2014-01-17 2015-01-16 Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci

Country Status (2)

Country Link
KR (1) KR20150086429A (fr)
WO (1) WO2015108372A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136922A1 (fr) * 2016-02-08 2017-08-17 Junaxo, Inc. Utilisation de tréhalose pour le traitement de maladies neurologiques
CN114342879A (zh) * 2022-02-14 2022-04-15 北京端点医药研究开发有限公司 一种神经退行性疾病的动物模型的构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110085260A (ko) * 2010-01-19 2011-07-27 경상대학교산학협력단 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110085260A (ko) * 2010-01-19 2011-07-27 경상대학교산학협력단 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NARASIMHAN, M. L. ET AL.: "Osmotin Is a Homolog of Mammalian Adiponectin and Controls Apoptosis in Yeast through a Homolog of Mammalian Adiponectin Receptor", MOLECULAR CELL, vol. 17, 21 January 2005 (2005-01-21), pages 171 - 180, XP002380322 *
NASEER, M. I.: "Neuroprotective effect against ethanol induced modulation of siRNA-mediated GABA(B) receptor and apoptotic neurodegeneration in the developing rat brain", THESIS OF GYEONGSANG NATIONAL UNIVERSIT Y, 2010 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136922A1 (fr) * 2016-02-08 2017-08-17 Junaxo, Inc. Utilisation de tréhalose pour le traitement de maladies neurologiques
US10736909B2 (en) 2016-02-08 2020-08-11 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
CN114342879A (zh) * 2022-02-14 2022-04-15 北京端点医药研究开发有限公司 一种神经退行性疾病的动物模型的构建方法

Also Published As

Publication number Publication date
KR20150086429A (ko) 2015-07-28

Similar Documents

Publication Publication Date Title
WO2019103203A1 (fr) Nouveau peptide et composition le comprenant
WO2017078499A2 (fr) Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase
WO2018169282A2 (fr) Composition pharmaceutique contenant de l'atpif1 pour le traitement du diabète
WO2018088862A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies neurodégénératives qui comprend un extrait de fleur de daphne genkwa ou des fractions de celui-ci en tant que substance active
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2018056706A1 (fr) Composition comprenant un peptide dérivé d'une protéine interagissant avec la thiorédoxine ou un polynucléotide codant pour celle-ci en tant que principe actif pour le vieillissement inverse d'une cellule souche âgée et son utilisation
WO2015108372A1 (fr) Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2013100718A2 (fr) Composition pharmaceutique permettant de prévenir ou de traiter des maladies inflammatoires ou l'asthme, contenant un extrait de lagerstroemia ovalifolia ou une fraction de celle-ci en tant que principe actif
WO2014042392A1 (fr) Composition à base de metformine pour la prévention ou le traitement de maladies immunes, notamment le lupus
WO2020122391A1 (fr) Composition pour la prévention ou le traitement de maladies associées à la sénescence cellulaire, contenant de l'homoharringtonine en tant que principe actif
WO2020116810A1 (fr) Composition pharmaceutique, comprenant un peptide inhibiteur contre la signalisation fas, destinée à la prévention ou au traitement de l'obésité, du foie gras, ou de la stéatohépatite
WO2013022139A1 (fr) Méthode de traitement de maladies provoquées par l'accumulation de bêta-amyloïdes dans le parenchyme cérébral par des dérivés thiazolidinediones à faible concentration
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2021033995A1 (fr) Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie
WO2017105081A1 (fr) Composition pharmaceutique pour le traitement de maladies pulmonaires ou l'atténuation des symptômes de maladies pulmonaires
WO2020189911A1 (fr) Composition comprenant de la noranhydroicaritine, pour la prévention ou le traitement de maladies métaboliques cardiovasculaires
WO2015072667A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies nerveuses crâniennes neurodégénératives
WO2020122392A1 (fr) Composition contenant du zotarolimus comme principe actif et destinée à la prévention ou au traitement de maladies liées à la sénescence cellulaire
WO2020122393A1 (fr) Composition pour prévenir ou traiter des maladies liées à la sénescence cellulaire comprenant de la salinomycine en tant que principe actif
WO2020106048A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie neurodégénérative
WO2015102205A1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer et contenant un inhibiteur des protéasomes et du lopéramide en tant que principes actifs
WO2019198982A1 (fr) Composition pour prévenir ou améliorer l'atrophie musculaire squelettique contenant de la kukoamine a et de la kukoamine b en tant que principes actifs
WO2018143615A1 (fr) Composition pharmaceutique contenant un inhibiteur d'activité de protéine peroxyrédoxine 1 en tant que substance active pour prévenir ou traiter une maladie osseuse
WO2019098568A2 (fr) Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15736971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15736971

Country of ref document: EP

Kind code of ref document: A1